<b>Background</b>: Although anti-CD38 monoclonal antibody-based regimens are standard care for newly diagnosed multiple myeloma (NDMM), direct comparative efficacy and comprehensive real-world safety data remain scarce. This evidence concerns the gene CD38 and plasma cell myeloma.